Exosome‐Engineered Afterglow Probe for Targeted Imaging of Atherosclerotic Plaques In Vivo
Advanced Healthcare Materials · 2026-01 · 15 (1)
DOI: 10.1002/adhm.202503261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 14.09.2025. Verfasst von Yating He und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry, Institute of Analytical Chemistry for Life Science, Zhengzhou University, Zhengzhou, 450001, China. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Exosomes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Henan Province, National Key Research and Development Program.
Abstract (Originalsprache)
Atherosclerosis is considered one of the primary causes of cardiovascular diseases, and thus assessing the vulnerability of atherosclerotic plaques is significant for timely clinical intervention. However, current probes for assessing vulnerable plaques face the dual challenges of insufficient imaging contrast and limited targeting specificity. Here, these limitations are addressed by applying an exosome‐engineered afterglow nanoprobe, which is developed by integrating M2 macrophage‐derived exosomes (M2 exosomes) with an afterglow luminescent agent for high‐contrast atherosclerotic plaque imaging. The nanoprobe features: 1) M2 exosome‐mediated active targeting performance to foam cell‐enriched vulnerable plaques through intrinsic inflammation tropism and 2) reactive oxygen species‐responsive afterglow amplification via H 2 O 2 ‐triggered chemically initiated energy transfer between the oxalate and afterglow agent. This probe could differentiate foam cells from normal macrophages (1.7‐fold higher uptake). In vivo results show that it precisely localizes in the plaques of ApoE −/− mice, demonstrating exceptional specificity. Moreover, imaging with the probe enables the visualization of carotid atherosclerotic plaques in living mouse models, with superior imaging contrast (2.25‐fold higher) compared with fluorescence signal. This targeted afterglow imaging agent represents a promising strategy for the non‐invasive identification of high‐risk atherosclerotic plaques, offering significant potential for guiding precision therapies and improving cardiovascular outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry, Institute of Analytical Chemistry for Life Science, Zhengzhou University, Zhengzhou, 450001, China.
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, China.
ORCID-Profile: Zhaohui Li
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Henan Province
- National Key Research and Development Program
- National Key Research and Development Program of China
Zitieren
APA
He, Y., Dong, X., Zhao, D., Han, C., Jia, Z., Meng, H. M., & Li, Z. (2026). Exosome‐Engineered Afterglow Probe for Targeted Imaging of Atherosclerotic Plaques In Vivo. Advanced Healthcare Materials, 15(1). https://doi.org/10.1002/adhm.202503261
Vancouver
He Y, Dong X, Zhao D, Han C, Jia Z, Meng HM, et al. Exosome‐Engineered Afterglow Probe for Targeted Imaging of Atherosclerotic Plaques In Vivo. Advanced Healthcare Materials. 2026;15(1). doi:10.1002/adhm.202503261
BibTeX
@article{He2026,
author = {He, Yating and Dong, Xintong and Zhao, Di and Han, Chen and Jia, Zhihui and Meng, Hong-Min and Li, Zhaohui},
title = {Exosome‐Engineered Afterglow Probe for Targeted Imaging of Atherosclerotic Plaques In Vivo},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {1},
doi = {10.1002/adhm.202503261}
}
EUVIMED